Prevalence of RPGR-Mediated Retinal Dystrophy in an Unselected Cohort of Over 5000 Patients.


Journal

Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919

Informations de publication

Date de publication:
03 01 2022
Historique:
entrez: 5 1 2022
pubmed: 6 1 2022
medline: 27 1 2022
Statut: ppublish

Résumé

Comprehensive genetic testing for inherited retinal dystrophy (IRD) is challenged by difficult-to-sequence genomic regions, which are often mutational hotspots, such as RPGR ORF15. The purpose of this study was to evaluate the diagnostic contribution of RPGR variants in an unselected IRD patient cohort referred for testing in a clinical diagnostic laboratory. A total of 5201 consecutive patients were analyzed with a clinically validated next-generation sequencing (NGS)-based assay, including the difficult-to-sequence RPGR ORF15 region. Copy number variant (CNV) detection from NGS data was included. Variant interpretation was performed per the American College of Medical Genetics and Genomics guidelines. A confirmed molecular diagnosis in RPGR was found in 4.5% of patients, 24.0% of whom were females. Variants in ORF15 accounted for 74% of the diagnoses; 29% of the diagnostic variants were in the most difficult-to-sequence central region of ORF15 (c.2470-3230). Truncating variants made up the majority (91%) of the diagnostic variants. CNVs explained 2% of the diagnostic cases, of which 80% were one- or two-exon deletions outside of ORF15. Our findings indicate that high-throughput, clinically validated NGS-based testing covering the difficult-to-sequence region of ORF15, in combination with high-resolution CNV detection, can help to maximize the diagnostic yield for patients with IRD. These results demonstrate an accurate and scalable method for the detection of RPGR-related variants, including the difficult-to-sequence ORF15 hotspot, which is relevant given current and emerging therapeutic opportunities.

Identifiants

pubmed: 34985506
pii: 2778227
doi: 10.1167/tvst.11.1.6
pmc: PMC8742508
doi:

Substances chimiques

Eye Proteins 0
RPGR protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6

Références

Am J Hum Genet. 2003 Nov;73(5):1131-46
pubmed: 14564670
Genet Med. 2020 Jun;22(6):1079-1087
pubmed: 32037395
Invest Ophthalmol Vis Sci. 2013 Feb 19;54(2):1411-6
pubmed: 23372056
Hum Mutat. 2002 May;19(5):486-500
pubmed: 11968081
Mol Vis. 2008 Jun 06;14:1081-93
pubmed: 18552978
PLoS Comput Biol. 2016 Apr 21;12(4):e1004873
pubmed: 27100738
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Arch Ophthalmol. 2007 Feb;125(2):151-8
pubmed: 17296890
Expert Opin Orphan Drugs. 2018 Feb 27;6(3):167-177
pubmed: 30057863
Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):4123-4133
pubmed: 30105367
Nat Protoc. 2016 Jan;11(1):1-9
pubmed: 26633127
Invest Ophthalmol Vis Sci. 2012 Dec 13;53(13):8232-7
pubmed: 23150612
Invest Ophthalmol Vis Sci. 2018 Sep 4;59(11):4434-4440
pubmed: 30193314
J Med Genet. 2016 Sep;53(9):600-7
pubmed: 27208209
J Mol Diagn. 2016 Nov;18(6):817-824
pubmed: 27620828
Ophthalmology. 2017 Sep;124(9):1314-1331
pubmed: 28559085
Prog Retin Eye Res. 2021 May;82:100898
pubmed: 32860923
Genes (Basel). 2019 Sep 04;10(9):
pubmed: 31487940
Nat Methods. 2014 Apr;11(4):361-2
pubmed: 24681721
Invest Ophthalmol Vis Sci. 2014 Aug 05;55(10):6213-23
pubmed: 25097241
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Am J Hum Genet. 2017 Jan 5;100(1):75-90
pubmed: 28041643

Auteurs

Sari Tuupanen (S)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Kimberly Gall (K)

Blueprint Genetics Inc, Seattle, WA, USA.

Johanna Sistonen (J)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Inka Saarinen (I)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Kati Kämpjärvi (K)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Kirsty Wells (K)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Katja Merkkiniemi (K)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Pernilla von Nandelstadh (P)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Laura Sarantaus (L)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Johanna Känsäkoski (J)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Emma Mårtenson (E)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Hanna Västinsalo (H)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Jennifer Schleit (J)

Blueprint Genetics Inc, Seattle, WA, USA.

Eeva-Marja Sankila (EM)

Helsinki University Eye Hospital, Outpatient Clinic for Hereditary Eye Diseases, Helsinki, Finland.

Annakarin Kere (A)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Heidi Junnila (H)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Pauli Siivonen (P)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Margarita Andreevskaya (M)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Ville Kytölä (V)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Mikko Muona (M)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Pertteli Salmenperä (P)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Samuel Myllykangas (S)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Juha Koskenvuo (J)

Blueprint Genetics OY, Keilaranta, Espoo, Finland.

Tero-Pekka Alastalo (TP)

Blueprint Genetics Inc, Seattle, WA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH